Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol Pollock

Showing results (111-120 of 162) with videos related to

Pageof 17
Sort By:
Plos One|July 25, 2022
Empowering faculty to initiate STEM education transformation: Efficacy of a systems thinking approachStasinos Stavrianeas, Gita Bangera, Claire Bronson, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 31, 2023
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE TrialSjoukje van der Hoek, Niels Jongs, Megumi Oshima, et al.
American Journal of Nephrology|August 22, 2024
The Lived Experience of Patients with Chronic Kidney Disease: Insights From DISCOVER CKDCarol Pollock, Juan-Jesus Carrero, Eiichiro Kanda, et al.
Journal of Cardiac Failure|March 1, 2026
SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to <20ml/min/1.73m<sup>2</sup>Safia Chatur, Robert A Fletcher, Emily Yeung, et al.
Kidney International Reports|February 12, 2024
Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A <i>Post Hoc</i> Analysis of CREDENCE TrialAkihiko Koshino, Brendon L Neuen, Megumi Oshima, et al.
The Lancet. Diabetes & Endocrinology|October 16, 2020
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trialMegumi Oshima, Brendon L Neuen, Meg J Jardine, et al.
Diabetes Care|March 13, 2020
Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 StudyLouisa Sukkar, Amy Kang, Carinna Hockham, et al.
Advances in Therapy|July 3, 2024
Clinical Outcomes in Patients with CKD and Rapid or Non-rapid eGFR Decline: A Report from the DISCOVER CKD Retrospective CohortHiddo Heerspink, Stephen Nolan, Juan-Jesus Carrero, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 14, 2025
SGLT2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome TrialsMegumi Oshima, Luke Buizen, Niels Jongs, et al.
Kidney International Supplements|January 25, 2019
Genetic and environmental risk factors for chronic kidney diseaseGregorio T Obrador, Ulla T Schultheiss, Matthias Kretzler, et al.
Pageof 17

Showing results (111-120 of 162) with videos related to

Sort By:
Pageof 17
Plos One|July 25, 2022
Empowering faculty to initiate STEM education transformation: Efficacy of a systems thinking approachStasinos Stavrianeas, Gita Bangera, Claire Bronson, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 31, 2023
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE TrialSjoukje van der Hoek, Niels Jongs, Megumi Oshima, et al.
American Journal of Nephrology|August 22, 2024
The Lived Experience of Patients with Chronic Kidney Disease: Insights From DISCOVER CKDCarol Pollock, Juan-Jesus Carrero, Eiichiro Kanda, et al.
Journal of Cardiac Failure|March 1, 2026
SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to <20ml/min/1.73m<sup>2</sup>Safia Chatur, Robert A Fletcher, Emily Yeung, et al.
Kidney International Reports|February 12, 2024
Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A <i>Post Hoc</i> Analysis of CREDENCE TrialAkihiko Koshino, Brendon L Neuen, Megumi Oshima, et al.
The Lancet. Diabetes & Endocrinology|October 16, 2020
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trialMegumi Oshima, Brendon L Neuen, Meg J Jardine, et al.
Diabetes Care|March 13, 2020
Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 StudyLouisa Sukkar, Amy Kang, Carinna Hockham, et al.
Advances in Therapy|July 3, 2024
Clinical Outcomes in Patients with CKD and Rapid or Non-rapid eGFR Decline: A Report from the DISCOVER CKD Retrospective CohortHiddo Heerspink, Stephen Nolan, Juan-Jesus Carrero, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 14, 2025
SGLT2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome TrialsMegumi Oshima, Luke Buizen, Niels Jongs, et al.
Kidney International Supplements|January 25, 2019
Genetic and environmental risk factors for chronic kidney diseaseGregorio T Obrador, Ulla T Schultheiss, Matthias Kretzler, et al.
Pageof 17